diabetes

Sanofi and Amgen, eyeing boost for PCSK9 use, tout benefits for diabetes patients
Sanofi and Amgen, eyeing boost for PCSK9 use, tout benefits for diabetes patients
Fierce Pharma
Sanofi
Amgen
PCSK9 inhibitors
diabetes
Regeneron
Praluent
Repatha
Flag link:
Severe hypoglycemia multiplies death risk up to fourfold in diabetes, Novo Nordisk finds
Severe hypoglycemia multiplies death risk up to fourfold in diabetes, Novo Nordisk finds
Fierce Pharma
Novo Nordisk
diabetes
hypoglycemia
EASD
Flag link:
AstraZeneca's Bydureon fails to show cardio-protection
AstraZeneca's Bydureon fails to show cardio-protection
BioPharma Dive
EASD
AstraZeneca
Bydureon
diabetes
Flag link:
EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point
EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point
Fierce Pharma
EASD
Boehringer Ingelheim
Eli Lilly
Jardiance
diabetes
Flag link:
EASD: AstraZeneca's Farxiga cuts blood sugar, weight and insulin use in Type 1 study
EASD: AstraZeneca's Farxiga cuts blood sugar, weight and insulin use in Type 1 study
Fierce Pharma
EASD
AstraZeneca
Farixga
diabetes
Flag link:
EASD: Sanofi's Toujeo bests Lantus at holding off hypoglycemia, studies show
EASD: Sanofi's Toujeo bests Lantus at holding off hypoglycemia, studies show
Fierce Pharma
Sanofi
EASD
Toujeo
Lantus
hypoglycemia
diabetes
Flag link:
MannKind - Afrezza Scripts Finish August Flat
MannKind - Afrezza Scripts Finish August Flat
Seeking Alpha
MannKind
Afrezza
diabetes
inhaled insulin
Flag link:
Big pharma stands to make hundreds of billions of dollars from a handful of medical conditions
Big pharma stands to make hundreds of billions of dollars from a handful of medical conditions
Motley Fool
Big Pharma
viral hepatitis
respiratory disease
autoimmune disease
cardiovascular disease
pain
diabetes
cancer
Flag link:
Sanofi wins tentative FDA nod for Admelog insulin lispro injection
Sanofi wins tentative FDA nod for Admelog insulin lispro injection
Drug Delivery Business News
Sanofi
FDA
Admelog insulin lispro
diabetes
Flag link:
Novo’s Victoza, new indication to reduce CV risk
Novo’s Victoza, new indication to reduce CV risk
GoInPharma
Novo Nordisk
Victoza
diabetes
cardiovascular disease
Flag link:
FDA clears Novo Nordisk's diabetes drug to reduce cardiovascular risk
FDA clears Novo Nordisk's diabetes drug to reduce cardiovascular risk
Yahoo/Reuters
Novo Nordisk
FDA
diabetes
Victoza
Flag link:
Januvia and Janumet: An Update on Merck’s Diabetes Franchise after 2Q17
Januvia and Janumet: An Update on Merck’s Diabetes Franchise after 2Q17
Market Realist
Merck
diabetes
Januvia
Janumet
Flag link:
Medtronic Hit by High Demand for Diabetes Devices
Medtronic Hit by High Demand for Diabetes Devices
Qmed
Medtronic
devices
diabetes
insulin pumps
Flag link:
Diabetes drugs must prove their value to payers, analysts say
Diabetes drugs must prove their value to payers, analysts say
Medical Marketing and Media
diabetes
payers
Novo Nordisk
semaglutide
Eli Lilly
Trulicity
Flag link:
The best drug is not always a guarantee for the best financial results
The best drug is not always a guarantee for the best financial results
GoInPharma
Novo Nordisk
Tresiba
diabetes
insulin
Flag link:
CVS formulary knocks Lilly, BI's Jardiance in favor of J&J's Invokana
CVS formulary knocks Lilly, BI's Jardiance in favor of J&J's Invokana
Fierce Pharma
formulary
Eli Lilly
Boehringer Ingelheim
JNJ
Invokana
diabetes
CVS Caremark
Flag link:
Diabetes Crisis Continues To Rage, But Biopharma's Response Is Tepid
Diabetes Crisis Continues To Rage, But Biopharma's Response Is Tepid
Forbes
diabetes
R&D
Flag link:
Despite scoring an FDA nod, Merck's biosim Lusduna must wait to challenge Lantus
Despite scoring an FDA nod, Merck's biosim Lusduna must wait to challenge Lantus
Fierce Pharma
FDA
Merck
biosimilars
Lusduna Nexvue
Lantus
diabetes
Sanofi
Hatch Waxman Act
Flag link:
Why Abbott’s CEO is excited about Bigfoot Biomedical and diabetes treatment
Why Abbott’s CEO is excited about Bigfoot Biomedical and diabetes treatment
Drug Delivery Business News
Abbott Labs
devices
diabetes
Miles White
Bigfoot Biomedical
Flag link:
MannKind: Afrezza Television Ad Debuts; What Investors Need To Know
MannKind: Afrezza Television Ad Debuts; What Investors Need To Know
Seeking Alpha
MannKind
Afrezza
drug ads
diabetes
investors
inhaled insulin
Flag link: